anti cd59 antibody  (Boster Bio)

Journal: Frontiers in Medicine

Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

doi: 10.3389/fmed.2025.1737919

Figure Lengend Snippet: Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).

Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

Techniques: Gene Expression, Expressing, Quantitative Proteomics

Journal: Frontiers in Medicine

Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

doi: 10.3389/fmed.2025.1737919

Figure Lengend Snippet: Kaplan–Meier survival curves showing the prognostic relevance of mRNA expression levels for CD59, SLC44A1, FCGR2B, TNFRSF13B, and CD320 genes. Cell populations with high expression of each gene are shown in blue, while populations with low expression of the same mRNA are shown in red. Reference datasets (GSE, GEO Series) are indicated at the top of each panel. Prognostic significance was assessed using the Cox proportional hazards model (95% confidence interval CI) and log-rank test, with p < 0.05 considered statistically significant.

Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

Techniques: Expressing

Journal: Frontiers in Medicine

Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

doi: 10.3389/fmed.2025.1737919

Figure Lengend Snippet: Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on different MM cell lines, including AMO-1, OPM-2, RPMI8226, U-266, and H929 as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker, allowing comparison of protein abundance across the different cell lines compared to unstained control (in blue).

Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

Techniques: Expressing, Flow Cytometry, Marker, Comparison, Quantitative Proteomics, Control

Journal: Frontiers in Medicine

Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

doi: 10.3389/fmed.2025.1737919

Figure Lengend Snippet: Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on malignant plasma cells (PCs) from eight bone marrow samples of newly diagnosed, untreated MM patients as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker across the eight MM patients samples, allowing comparison of protein abundance compared to unstained control (in blue).

Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

Techniques: Expressing, Clinical Proteomics, Flow Cytometry, Marker, Comparison, Quantitative Proteomics, Control